📊 INAB Key Takeaways
Is In8Bio, Inc.. (INAB) a Good Investment?
IN8BIO is a pre-revenue biotech company with no current commercial products, generating -$5.1M in annual losses while burning $4.9M in operating cash flow. While the company maintains strong liquidity ($21.9M cash) and a debt-free balance sheet providing approximately 4-5 years of runway, the absence of revenue, negative returns (ROE -22.3%, ROA -19.4%), and lack of insider confidence (zero Form 4 filings) indicate substantial execution and clinical development risk.
IN8bio is pre-revenue with sustained operating and net losses, and profitability shows no improvement YoY despite an apparent EPS improvement likely driven by dilution. The balance sheet is strong (high cash, no debt, very high current ratio), providing ~2 years of runway at the current burn, but there is no evidence of revenue traction or improving unit economics. Until operating burn narrows or revenue begins, fundamentals warrant caution.
In8Bio, Inc.. Key Strengths (INAB)
- Strong liquidity position with $21.9M in cash (83% of total assets)
- Extremely healthy current ratio of 10.50x indicating short-term financial stability
- Clean balance sheet with zero debt and manageable liabilities ($3.5M)
- Robust liquidity and cash balance with no debt
- Very low liabilities and strong current ratio (8.8x)
- Clean capital structure supports near-term operations
INAB Stock Risks: In8Bio, Inc.. Investment Risks
- Zero revenue generation indicating no commercial viability yet
- Negative shareholder returns (ROE -22.3%, ROA -19.4%) signaling value destruction
- Annual cash burn of $4.9M limits runway to approximately 4-5 years without additional funding
- Pre-clinical/early-stage biotech with uncertain timeline to profitability
- Absence of insider buying activity (0 Form 4 filings) suggests limited insider confidence
- Significant execution risk dependent on successful drug development and regulatory approval
- Persistent operating losses with no revenue
- Dilution risk to fund ongoing R&D and trials
- Execution and regulatory uncertainty typical of clinical-stage biotech
Key Metrics to Watch
- Time to first revenue generation and commercial product launch
- Cash burn rate and remaining cash runway
- Clinical trial progress and regulatory milestones for pipeline candidates
- Operating cash flow (burn rate)
- Cash & equivalents / runway (months)
In8Bio, Inc.. (INAB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.50x current ratio provides a solid financial cushion.
INAB Profit Margin, ROE & Profitability Analysis
INAB vs Healthcare Sector: How In8Bio, Inc.. Compares
How In8Bio, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is In8Bio, Inc.. Stock Overvalued? INAB Valuation Analysis 2026
Based on fundamental analysis, In8Bio, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
In8Bio, Inc.. Balance Sheet: INAB Debt, Cash & Liquidity
INAB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: In8Bio, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-17.05 indicates the company is currently unprofitable.
INAB Revenue Growth, EPS Growth & YoY Performance
In8Bio, Inc.. Dividends, Buybacks & Capital Allocation
INAB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for In8Bio, Inc.. (CIK: 0001740279)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INAB
What is the AI rating for INAB?
In8Bio, Inc.. (INAB) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INAB's key strengths?
Claude: Strong liquidity position with $21.9M in cash (83% of total assets). Extremely healthy current ratio of 10.50x indicating short-term financial stability. ChatGPT: Robust liquidity and cash balance with no debt. Very low liabilities and strong current ratio (8.8x).
What are the risks of investing in INAB?
Claude: Zero revenue generation indicating no commercial viability yet. Negative shareholder returns (ROE -22.3%, ROA -19.4%) signaling value destruction. ChatGPT: Persistent operating losses with no revenue. Dilution risk to fund ongoing R&D and trials.
What is INAB's revenue and growth?
In8Bio, Inc.. reported revenue of N/A.
Does INAB pay dividends?
In8Bio, Inc.. does not currently pay dividends.
Where can I find INAB SEC filings?
Official SEC filings for In8Bio, Inc.. (CIK: 0001740279) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INAB's EPS?
In8Bio, Inc.. has a diluted EPS of $-0.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is INAB's fundamental grade?
Based on our AI fundamental analysis in June 2026, In8Bio, Inc.. has a C grade with 66% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is INAB stock overvalued or undervalued?
Valuation metrics for INAB: ROE of -22.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is INAB's AI grade for 2026?
Our dual AI analysis gives In8Bio, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INAB's free cash flow?
In8Bio, Inc..'s operating cash flow is $-4.9M, with capital expenditures of $0.0.
How does INAB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -22.3% (avg: 15%), current ratio 10.50 (avg: 2).